158
Participants
Start Date
March 31, 2008
Primary Completion Date
October 31, 2009
Study Completion Date
October 31, 2009
Anti-CD137 (4-1BB) (BMS-663513)
IV solution, IV, until PD or toxicity
Local Institution, Aarhus C
Mem Sloan-Ket Can Ctr, New York
Local Institution, Genove
Local Institution, Milan
Harry & Jeanette Weinberg Cancer Inst At Franklin Square, Baltimore
Local Institution, Kiel
Blumenthal Cancer Center, Carolinas Medical Center, Charlotte
Local Institution, Padua
Indiana University Melvin And Bren Simon Cancer Center, Indianapolis
Local Institution, Siena
Local Institution, Vandœuvre-lès-Nancy
Local Institution, Mainz
Local Institution, Lille
Oncology Specialists, S.C., Park Ridge
Local Institution, Homburg / Saar
Local Institution, Mannheim
Local Institution, Tübingen
Local Institution, Paris
Local Institution, Paris
University Of Texas, Houston
Local Institution, Napoli
The Angeles Clinic & Research Institute, Los Angeles
Local Institution, Villejuif
Local Institution, Würzburg
Providence Portland Medical Center, Portland
Yale University School Of Medicine, New Haven
Dana-Farber Cancer Inst, Boston
Local Institution, Calgary
Local Institution, Edmonton
Local Institution, Montreal
Local Institution, Odense C
Local Institution, Jena
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY